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Introduction {#sec001}
============

Lyme disease, caused by the spirochete *Borrelia burgdorferi* (*Bb*), is the most commonly reported vector-borne disease in the United States--with 30,000 cases being reported to the CDC annually \[[@pone.0234993.ref001], [@pone.0234993.ref002]\]. Like many other diseases, *B*. *burgdorferi* is subject to underreporting, as demonstrated by two studies conducted by the CDC that concluded an estimated 300,000 individuals are infected with Lyme disease each year in the U.S \[[@pone.0234993.ref003], [@pone.0234993.ref004]\]. Associated medical costs of initial treatment and extended healthcare for ongoing symptoms attributed to post-treatment Lyme disease syndrome (PTLDS) are estimated to be between \$712 million---\$1.3 billion each year \[[@pone.0234993.ref005]\].

The symptoms of Lyme disease can range from erythema migrans to more systematic disorders such as arthritis and neurological complications, termed neuroborreliosis \[[@pone.0234993.ref006], [@pone.0234993.ref007]\]. Manifestations of neuroborreliosis include radiculoneuritis, meningitis, and facial palsy \[[@pone.0234993.ref008]--[@pone.0234993.ref010]\]. It is well-documented that *B*. *burgdorferi* is capable of penetrating into the central nervous system (CNS). This is evident from the direct detection of the pathogen within the cerebral spinal fluid, usually performed by lumbar puncture, followed by bacterial culture or PCR \[[@pone.0234993.ref011]\]. Furthermore, other methods suggest of CNS invasion---the detection of intrathecal antibodies, an increase in peripheral immune cells, such as lymphocytic pleocytosis, and the presence of the chemoattractant *cxcl13* \[[@pone.0234993.ref012]--[@pone.0234993.ref015]\]. Though methods of detection and diagnosis of neuroborreliosis continue to grow, very little is known about the mechanisms by which *B*. *burgdorferi* enters the CNS and the pathophysiology of the disease. *B*. *burgdorferi* does not produce or secrete any known toxins and it is suggested that the host inflammatory response elicited by the bacteria is a factor in the pathogenesis of the disease \[[@pone.0234993.ref016]--[@pone.0234993.ref018]\]. Explants and primary cultures of dorsal root ganglia tissue from rhesus macaques that were incubated with *Borrelia burgdorferi* showed an increase in inflammatory cytokines *ccl2*, *il-6*, and *il-8*, as well as the apoptosis of sensory neurons \[[@pone.0234993.ref019]\]. The correlation between inflammation and the pathology of the disease is also observed in the inflammation and subsequent apoptosis of oligodendrocyte cultures following *Bb* infection \[[@pone.0234993.ref020]\]. This is further seen in the cerebral spinal fluid (CSF) of patients with confirmed neuroborreliosis that show increases in chemokines such as *ccl2*, *ccl5*, and *cxcl1* \[[@pone.0234993.ref021]--[@pone.0234993.ref023]\]. The presence of these chemokines may indicate a role for these factors in the host immune response, notably immune cell trafficking.

The choroid plexus (CP) is one such complex that has been implicated in the trafficking of immune cells across its blood-CSF-barrier (BCSFB). In addition to its role in the formation of the BCSFB, it is the major producer of CSF \[[@pone.0234993.ref024], [@pone.0234993.ref025]\]. The CP is a highly vascularized structure within the ventricles of the brain, and unlike the blood-brain barrier (BBB), the capillaries within the choroid plexus are highly fenestrated. Instead, the epithelial layer is responsible for the selective permeability of the BCSFB through the formation of tight and adherens junctions \[[@pone.0234993.ref026]\]. An interesting characteristic of the choroid plexus is the presence of immune cells on the basolateral side within the stromal matrix--this includes dendritic cells and macrophages ([Fig 1](#pone.0234993.g001){ref-type="fig"}) \[[@pone.0234993.ref027]--[@pone.0234993.ref030]\]. Further illustration of the immune-surveillance role of the choroid plexus is shown in the presence of cell adhesion molecules on CP epithelium and not the neighboring endothelium, which mediate the binding of immune cells \[[@pone.0234993.ref031]\]. The transmigration of macrophages and peripheral blood mononuclear cells (PBMCs) across the choroid plexus epithelium was observed in transwell and explant cultures in the presence of feline immunodeficiency virus \[[@pone.0234993.ref032]\]. In a human barrier model of the choroid plexus, the transepithelial migration of polymorphonuclear neutrophils and monocytes were observed following bacterial infection (*Neisseria meningitidis*) \[[@pone.0234993.ref032]\]. It is understood that the context of a bacterial infection and the inflammatory profile of the CSF determines the severity and overall outcome of patients \[[@pone.0234993.ref033]--[@pone.0234993.ref035]\]; therefore, due to the choroid plexus's anatomical position in separating the periphery and CNS, as well as its secretory, barrier, and immune response roles, the intent of this project was to investigate the effects of *Borrelia burgdorferi* infection on choroid plexus epithelial cells.

![Structural features of the choroid plexus.\
Under healthy conditions, the choroid plexus maintains peripheral immune cells within the stromal matrix as a form of immunosurveillance. Multiple receptors are present on the epithelium, including cytokine and pattern recognition receptors. The BCSFB is formed by the epithelium through tight junctions, adherens junctions, and desmosomes. During infection or disease states, these junctions may be altered, immune cells may transmigrate across the epithelium, and cytokines from both the epithelial cells and activated immune cells are released. Many of these cytokines induce a pro-inflammatory response and act as chemoattractants for innate and adaptive immune cells. Created with [Biorender.com](http://Biorender.com).](pone.0234993.g001){#pone.0234993.g001}

The overall aim of this study is to determine the transcriptome profile of primary human choroid plexus epithelial cells (HCPECs) during *B*. *burgdorferi* infection. Using HCPECs in culture, we demonstrated differential expression of 258 genes following infection with *B*. *burgdorferi* after 48 hours. Functional and pathway analysis of these transcriptional changes revealed upregulation of host inflammatory and immune responses, related to interferon, chemokine, and cytokine pathways, as well as immune cell trafficking and activation. Although this model does not provide a barrier context, interestingly, functional and cellular components involving cell-cell junctions and tight junctions were seen to be downregulated. Here we present our findings of differential gene expression in HCPECs following infection with *B*. *burgdorferi*.

Methods {#sec002}
=======

Bacteria culture {#sec003}
----------------

The *Borrelia burgdorferi* strain B31-MI-16 is an infectious clone which was previously sequenced and described \[[@pone.0234993.ref036], [@pone.0234993.ref037]\]. Bacteria cultures were grown to approximately 1 x 10^7^ bacteria/ml in modified Barbour-Stoenner-Kelly (BSK-II) medium supplemented with 6% rabbit serum at 34°C and used at passage 2.

Cell culture {#sec004}
------------

HCPECs were obtained from ScienCell Research Laboratories (Carlsbad, CA; catalog \#1310). Commercially available human primary cell cultures and protocols used throughout this study followed the University of North Dakota IRB guidelines outlined in form 504 "Categories of Research", section 2.19 "Commercially Available Human Biological Specimens (45 CFR 46.102, 46.103, and 46.116" and therefore do not require IRB review. Purity of cells was assessed and confirmed by immunofluorescence, the following primary antibodies and concentrations were used: Rabbit anti-Prealbumin (TTR) conjugated to Alexa Fluor 488 (Abcam, catalog \#ab199074; Conc. 1:50), Mouse anti-α-Tubulin (Sigma, catalog \#T61999; Conc. 2 μg/ml), Mouse anti-CK18 (Abcam, catalog \#ab82254; Conc. 1:50). The secondary antibody, Donkey anti-Mouse conjugated to Alexa Fluor 594 (Jackson Immunoresearch, catalog \#715-585-151, Conc. 1:100), was used for anti-CK18 and anti-α-Tubulin antibodies. For immunofluorescence, cells were grown on glass coverslips and fixed with a 4% paraformaldehyde solution for 15 minutes and stored in PBS at 4°C. Permeabilization was performed with a 0.1% Triton-PBS solution for 10 minutes and blocked with a 10% Donkey (Jackson immunoresearch, catalog \#017-000-121) or Goat Serum (Jackson Immunoresearch, catalog \#005-000-121) in 0.1% Tween-PBS solution for 1 hour. Primary antibodies were incubated overnight at 4°C. Secondary antibodies were incubated for 1 hour at room temperature. DAPI Fluoromount-G (SouthernBiotech, catalog \#0100--20) was used for nuclei staining. Western blot analysis was performed on control and infected cell lysates to determine presence of TTR and CK18 --previously mentioned primary antibodies were used in conjunction with the secondary antibodies: Donkey anti-rabbit conjugated to peroxidase (Jackson Immunoresearch, catalog \#711-035-152, Conc. 1:200,000) and Goat anti-mouse conjugated to peroxidase (Jackson Immunoresearch, catalog \#115-035-003, Conc. 1:200,000). Signal was produced by SuperSignal West Femto Maximum Sensitivity Substrate kit from ThermoFisher Scientific (catalog \#34094) and imaged on a Licor Odyssey Fc Imaging System.

Cells were maintained in tissue-treated vented cap T-75 flasks (Corning, catalog \#430641U) in epithelial cell medium (ScienCell, catalog \#4101), containing antibiotics penicillin (100 units/ml) and streptomycin (100 ug/ml) (ScienCell, catalog \#0503), 2% fetal bovine serum (ScienCell, catalog \#0010), and EpiCGS (ScienCell, catalog \#4125). Two groups were used for these experiments--Control, non-infected (n = 3) and Infected, 48 hours (n = 3); a total of 6 samples. Cells were incubated at 37°C and used at passage 3 at approximately 80% confluence for stimulation by *Bb*. Prior to infection, the cell cultures were washed 3 times with sterile Dulbecco's phosphate buffered saline (DPBS) and the medium replaced with antibiotic-free epithelial cell medium. Cell cultures were stimulated with *B*. *burgdorferi* at a multiplicity of infection (MOI) of 10:1 (bacteria:cells) for 48 hours. Mean cell count of HCPECs was determined using an automated cell counter (Life Countess II, catalog \#AMQAX1000) to determine appropriate number of bacteria for infection. Control non-treated flasks were prepared identically without infection. Light microscopy was used to monitor cell morphology and confluency. Additionally, cell proliferation was monitored using an MTS assay (Abcam, catalog \#ab197010) and colorimetric plate reader in a 96-well plate under identical conditions. Apoptosis and necrosis were determined by fluorescence microscopy using Apopxin Green Indicator (Apoptosis) and 7-AAD (Necrosis) on cells grown in 24-well plates on glass coverslips under identical conditions (Abcam, catalog \#ab176749) and manually counted.

RNA isolation {#sec005}
-------------

RNA was isolated via phenol-chloroform extraction and using the RNeasy Mini kit from Qiagen (catalog \#74106) according to the manufacturer's instructions. In short, cell medium was removed from cultures and used for later protein analysis; 1 ml of trizol was added directly to each flask and a cell scraper was used to fully lyse all cells. Homogenized cells were transferred to RNase-DNase free 1.5 ml Eppendorf tubes, where chloroform was added for 2 minutes and centrifuged at 12,000 x g for 15 minutes at 4°C. The upper aqueous phase was mixed with 70% ethanol and placed in a Qiagen RNeasy Mini column. The flow-through was discarded and the bound RNA fraction remaining on the column membrane was further washed and processed per Qiagen's instructions. Genomic DNA was removed with DNA digestion with RNase-free DNase Set (Qiagen, catalog \#79254). RNA quality was assessed with a NanoDrop and integrity assessed by gel electrophoresis on a 2% agarose gel.

Library construction and RNA sequencing {#sec006}
---------------------------------------

Isolated total RNA, as described above, underwent further quality control and purification to obtain mRNA. To assess RNA integrity of total RNA, samples were placed in an Agilent 2100 Bioanalyzer with the RNA 6000 Nano kit (catalog \#5067--1511)--all samples passed with an RNA integrity number (RIN) of ≥8.9. To obtain a more accurate concentration, total RNA samples were run on a broad range Qubit 2.0 Fluorometer. mRNA was enriched from total RNA samples using the NEBNext Poly(A) mRNA Magnetic Isolation Module (catalog \#E7490S)--in short, oligo d(T) beads are used to bind the poly(A) tail of eukaryotic mRNA. The NEBNext Ultra II RNA-seq library kit (catalog \#E7775S) was used for library construction. Libraries were checked for quality and adaptor contamination on the bioanalyzer with the Agilent DNA 1000 kit (catalog \#5067--1504). Library concentration was assessed with a BioTek Gen5 Wellplate reader with the Quant-iT PicoGreen dsDNA Assay kit (catalog \#P11496). All samples, 3 control and 3 infected, were then pooled and sent to Novogene ([https://en.novogene.com](https://en.novogene.com/)) for sequencing. An Illumina HiSeq 4000 was used for 150 bp paired-end sequencing.

RNA data analysis {#sec007}
-----------------

Raw fastq files were received from Novogene and initial quality control was assessed using FastQC version 0.11.2 \[[@pone.0234993.ref038]\]. All samples passed initial QC following adaptor trimming using Trimmomatic \[[@pone.0234993.ref039]\]. Reads were aligned to the human (hg19) assembly using Hisat2, version 2.1.0 \[[@pone.0234993.ref040]\] and indexed by Samtools, version 1.9 \[[@pone.0234993.ref041]\]. Differential gene expression analysis was performed using DESeq2, version 1.24.0 \[[@pone.0234993.ref042]\], with an FDR of 0.05 or lower, and no fold change cut-off. Network mapping and functional analysis was performed with STRING database, version 11.0 \[[@pone.0234993.ref043]\] and verified with PANTHER, version 14.1 \[[@pone.0234993.ref044]\]. STRING utilizes Gene Ontology \[[@pone.0234993.ref045], [@pone.0234993.ref046]\] to determine functional enrichments within our networks.

Pathway analysis was performed using Signaling Pathway Impact Analysis (SPIA), version 2.36.0 \[[@pone.0234993.ref047], [@pone.0234993.ref048]\], which brings fold change and gene function into context. SPIA uses the Kyoto Encyclopedia of Genes and Genomes \[[@pone.0234993.ref049]\] (KEGG) database to determine impact of DEGs on the respective pathway based on gene enrichment and topology of the pathway. Pathway enrichment is determined from the total number of genes within a specific pathway compared to the Number of Differential Expressed genes (NDE) observed within that pathway; significance of pathway enrichment was set at pNDE \< 0.05. Furthermore, the topology of a pathway is taken into consideration to determine the impact of DEGs within that pathway. The perturbations (PERT) of a pathway caused by DEGs is determined based on the location of these genes within the pathway; significance was set to pPERT \< 0.05. Overall global significance (pG) was determined from pNDE and pPERT. Two forms of statistical corrections pG were performed--a Bonferroni correction (pGFWER) and a false discovery rate (FDR) correction (pGFDR). To determine significance of a pathway, pGFDR \< 0.05 was considered.

Validation of RNA-seq using RT-qPCR and cDNA synthesis {#sec008}
------------------------------------------------------

Selected individual transcripts were confirmed using PCR primer sets (Qiagen, catalog \#330001). cDNA from RNA samples were synthesized using Qiagen's First Strand Kit (catalog \#330404). Each reaction was performed following the RT^2^ qPCR Primer Assay instructions--each reaction contained 1 μl of the primer mix at 10 μM for each gene of interest, 12.5 μl RT^2^ SYBR Green Mastermix, 1 μl cDNA, and 10.5 μl Nuclease-free water, for a total reaction volume of 25 μl. qPCR was initiated with a single 10 min cycle at 95°C for initial denaturing and activation of polymerase. Following this, 40 cycles of 15 seconds at 95°C and 1 minute at 60°C was performed and fluorescent data was collected at the end of each cycle. Melt curve analysis was performed at the end of the reaction using the following conditions: 95°C, 1 min; 65°C, 2 mins; 65°C to 95°C step-wise at 2°C/min. Expression levels of transcripts were compared and normalized to the housekeeping gene *actb* (β-actin). Relative gene expression between treated and untreated sample groups were compared using the 2 --^ΔΔCT^ method. All samples were analyzed in triplicate from three biological replicates.

Supernatant protein analysis by enzyme-linked immunosorbent assays {#sec009}
------------------------------------------------------------------

Supernatants from cultures were removed as previously mentioned following treatment. Samples were aliquoted and stored at -20°C until use. ELISAs were performed following manufacturer's instructions (R&D Systems, DuoSet ELISA). Briefly, plates were coated and incubated overnight at room temperature with 100μl of capture antibody. Following aspiration of this antibody and washing, 100 μl of standards and sample were added to each well. Plates were than incubated at room temperature for 2 hours, aspirated, and then washed. 100 μl of conjugated detection antibody was then added to each well and incubated for 2 hours at room temperature. Colorimetric detection was performed after the addition of a chromogenic substrate and stop solution. Plates were read at a wavelength of 450 nm on a BioTek Epoch plate reader.

Statistical analysis {#sec010}
--------------------

Differential gene expression of RNA sequencing data was determined by DESeq2. Briefly, DESeq2 utilizes an empirical Bayes approach and makes the assumption that genes of similar transcript levels will show similar variability. Through this, the package can control for replicate variability at each specific gene by taking into consideration the average variability of similarly expressed genes, and account for sample size. Furthermore, DESeq2 performs a Benjamini-Hochberg adjustment resulting in an adjusted p-value (padj) also called a false discovery rate (FDR). Genes with an FDR \< 0.05 were considered significant.

Statistical analysis between control and infected groups for both RT-qPCR and ELISA was performed using an unpaired student's t-test using GraphPad Prism Version 8. Additional post-hoc analysis was performed on RT-qPCR to correct for multiple t-test comparisons. The method of Benjamini, Krieger, and Yekutieli was used to determine the FDR--this method is an updated version of the previously mentioned Benjamini-Hochberg adjustment \[[@pone.0234993.ref050]\]. Transcripts for RT-qPCR were considered significant if FDR \< 0.05 (\*) Protein levels from ELISA were considered significant if p \< 0.05 (\*).

Results {#sec011}
=======

Prior to infection, the identity and purity of HCPECs was assessed and confirmed through immunohistochemistry (IHC) with cytokeratin 18 (CK18), an epithelial cell marker, and transthyretin (TTR), a marker for choroid plexus epithelial cells and specific hepatocytes ([Fig 2A and 2B](#pone.0234993.g002){ref-type="fig"})-- 98% of cells were CK18 and TTR positive \[[@pone.0234993.ref051]\]. [Fig 2A](#pone.0234993.g002){ref-type="fig"} indicates the colocalization of TTR within CK18 labeled cells; [Fig 2B](#pone.0234993.g002){ref-type="fig"} further illustrates the cytoplasmic localization of TTR by using α-Tubulin to highlight cellular boundaries. Total protein from control and infected groups was isolated to check for the presence of CK18 and TTR ([Fig 2C](#pone.0234993.g002){ref-type="fig"}). The effects of *Bb* infection on HCPEC proliferation, apoptosis, and necrosis was measured through IHC and colorimetric assays---no significant changes were detected between infected and control groups.

![Characterization of primary HCPECs.\
(A) HCPECs were identified by immunostaining with cytokeratin 18 (CK18---red), an epithelial cell marker, and transthyretin (TTR--green), a transport protein predominantly expressed by choroid plexus epithelial cells and hepatocytes. Nuclei were stained with DAPI (blue). Magnification: 40x, Scalebar: 40 μm. Further observations of TTR localization within the cytoplasm of HCPECs. (B) Colocalization of α-Tubulin (red) and TTR (green); nuclei stained with DAPI (blue). Magnification: 60x, Scalebar: 40 μm. (C) Westernblot for the presence of CK18 and TTR (dimer). Lanes C1, C2, C3 --Uninfected HCPECs protein; Lanes I1, I2, I3 --Protein from HCPECs infected with *Bb* for 48 hours.](pone.0234993.g002){#pone.0234993.g002}

Stimulation of type I/II interferon signaling pathway following B. burgdorferi infection {#sec012}
----------------------------------------------------------------------------------------

*B*. *burgdorferi* infection was performed with primary human choroid plexus epithelial cell cultures for 48 hours, and changes in the transcriptome of the human cells were compared to untreated controls (3 biological replicates per group). Supernatant from each replicate was collected and used for protein analysis, and RNA was then isolated. Following RNA isolation, Illumina libraries were made and sequenced on an Illumina HiSeq 4000 as outlined in the Methods section. Differential gene expression analysis was performed using the DESeq2 package in Rstudio. Following count normalization, an MA-plot ([Fig 3A](#pone.0234993.g003){ref-type="fig"}) was constructed--this illustrates genome-wide transcriptome expression of the 48-hour *Bb* treated group when compared to the control group. Dots in red represent significant differentially expressed genes (DEGs), plotted as a function of its log~2~ fold change versus the mean of normalized counts. Using an adjusted p-value (false discovery rate) less than or equal to 0.05, and no fold change threshold, a total of 258 genes were shown to have significant differential expression ([S1 File](#pone.0234993.s001){ref-type="supplementary-material"}). Of these 258 DEGs, 160 were upregulated and 98 downregulated. A principal component analysis (PCA) plot was generated and shows clustering between treatment groups ([S1 Fig](#pone.0234993.s003){ref-type="supplementary-material"}). Hierarchical clustering of replicates based on treatment is further illustrated in the heatmap analysis ([Fig 3B](#pone.0234993.g003){ref-type="fig"}) of the 258 DEGs for each replicate.

![RNA-seq was performed on HCPECs that were infected by *B*. *burgdorferi* for 48 hours and from uninfected controls.\
(A) MA-plot representing gene expression patterns of infected group compared to control (n = 3). Red dots indicated significant differentially expressed genes (DEGs; FDR \<0.05). A total of 258 genes were differentially expressed. (B) A heatmap of the 258 DEGs showing clustering patterns between each biological replicate.](pone.0234993.g003){#pone.0234993.g003}

In order to validate our RNA-seq findings, RT-qPCR was performed on a set of select genes ([Fig 4A](#pone.0234993.g004){ref-type="fig"}). The upregulated genes *cxcl3*, *cxcl6*, *ccl5*, *ifit1*, and *ifitm1* were found to be significantly upregulated by RT-qPCR when comparing 48-hour infected group to the untreated group. Although *cxcl5* and *irf7* transcripts were not significantly increased, an increasing trend was observed that correlates with the RNA-seq data. Additionally, the downregulated genes *cdh2*, *flt1*, and *anxa1* showed a non-significant downward trend that corresponds with our previous data. In order to determine if transcriptional changes observed in response to *Bb* resulted in protein production and secretion from the choroid plexus epithelial cells, we measured the cytokine levels in cell culture supernatants by ELISA ([Fig 4B--4E](#pone.0234993.g004){ref-type="fig"}). Following 48-hours post *B*. *burgdorferi* stimulation, Cxcl1, Cxcl2, Cxcl5, and Cxcl6 supernatant concentrations were assessed. Cxcl1, Cxcl2, and Cxcl5 were induced and secreted at significantly higher levels in the infected samples compared to untreated controls. Though Cxcl6 did not show significant elevation, a similar increase in protein levels was observed. These data agree with our RNA-seq findings.

![Validation of RNA-seq gene expression data.\
(A) Select differentially expressed genes following 48-hour *B*. *burgdorferi* treatment were validated by RT-qPCR. Primers specific to *cxcl3*, *cxcl5*, *cxcl6*, *ccl5*, *ifit1*, *ifitm1*, *irf7*, *cdh2*, *flt1*, *anxa1*, and *actb* were used for amplification. The relative gene expression between 48-hour *B*. *burgdorferi* treated and untreated control groups are expressed as Log2FC and normalized to the housekeeping gene ACTB. Significance was calculated by Student's t-test (\* p\<0.05, n = 3). (B-E) Supernatant from infected and untreated groups were collected and analyzed by ELISA. Concentrations of these secreted cytokines are shown as the mean and standard deviation. Significance was calculated by Student's t-test followed by Benjamini, Krieger, Yekutieli correction (\* FDR \< 0.05, n = 3).](pone.0234993.g004){#pone.0234993.g004}

Both subsets of upregulated and downregulated genes were analyzed for known interactions of their associated proteins using the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins - <https://string-db.org/>) database (Figs [5](#pone.0234993.g005){ref-type="fig"} and [6](#pone.0234993.g006){ref-type="fig"}) \[[@pone.0234993.ref043]\]. STRING analysis provides insight into the protein-protein interactions of each gene--each node represents one of the DEGs; lines between nodes correspond to known interactions that were experimentally determined or curated from databases utilized by STRING. STRING also provides information on functional and pathway analysis through the use of Gene Ontology (GO) \[[@pone.0234993.ref045], [@pone.0234993.ref046]\] and KEGG \[[@pone.0234993.ref049]\]. Upregulated DEGs ([Fig 5A](#pone.0234993.g005){ref-type="fig"}) show two distinct clusters within the network. The first cluster, shown in the top left, is predominantly comprised of chemokines and cytokines--the red nodes denote genes within the chemokine-mediated signaling pathway (GO:0070098, FDR 8.23E-08). Additionally, the second highly clustered nodes situated within the center indicates genes associated with type I (blue) and type II (green) interferon pathways (GO:0060337, FDR 2.71E-23; GO:0034341, FDR 9.58E-15, respectively). The biological processes that were enriched predominantly involved inflammatory/immune response pathways and cell-cell communication ([Fig 5B](#pone.0234993.g005){ref-type="fig"}). A large subset of the upregulated genes was found to be interferon pathway genes ([Table 1](#pone.0234993.t001){ref-type="table"}). Of note, the interferon-induced protein family of genes, *ifit1*, *ifit3*, *ifitm1*, *ifitm2*, *ifitm3*, and others, were shown to be significantly upregulated. Type I and II interferon related genes, such as *gbp2*, *ifit1*, and *oasl*, have been previously reported as being significantly elevated as a consequence of *B*. *burgdorferi* infection \[[@pone.0234993.ref052], [@pone.0234993.ref053]\]. Furthermore, major transcription factors that were observed to be upregulated including *irf7*, *stat1*, and *stat2*, have been shown to play important roles in regulating the *Bb*-induced interferon response \[[@pone.0234993.ref054]--[@pone.0234993.ref056]\]. Interferon related genes have traditionally been associated with viral, not bacterial, infections, and this is reflected in regard to the labeling of gene function and pathway analysis within these data. However, it is well documented that such genes are often observed to play key roles during bacterial infections, including Lyme disease \[[@pone.0234993.ref057]--[@pone.0234993.ref060]\]. Signaling Pathway Impact Analysis (SPIA) was performed to determine pathway enrichment based on an increase in gene enrichment and position of genes within a pathway. A total of 14 pathways were identified as being significantly enriched ([Fig 7](#pone.0234993.g007){ref-type="fig"}). The top activated pathways involve the activation of viral pathways, including Influenza A, Measles, and Herpes simplex infection. As stated before, these viral pathways involve the interferon related response as observed in our data. These data imply that infection with *B*. *burgdorferi* produces a significant immune response that encapsulates major interferon-signaling pathways within HCPECs.

![Network and functional analysis of upregulated DEGs by STRING analysis.\
(A) String network--Each node represents a DEG; lines between nodes indicate known protein-protein interactions. Nodes in blue and green correspond to type I or type II interferon pathways, respectively; Red corresponds to chemokine-mediated signaling pathway. (B) Table of select GO enrichments.](pone.0234993.g005){#pone.0234993.g005}

![Network and functional analysis of downregulated DEGs by STRING analysis.\
(A) String network--Nodes in blue and green represent cell-cell junctions (GO:0005911) and bicellular tight junctions (GO:0005923), respectively. Nodes in red indicate genes within the focal adhesion pathway from KEGG pathway analysis (hsa04510). (B) Table of selected GO enrichments.](pone.0234993.g006){#pone.0234993.g006}

![Signaling pathway impact analysis.\
SPIA of all DEGs based on pathway gene enrichment (pNDE) and pathway perturbations (pPERT) that take into account gene placement and topology within the pathway. Both pNDE and pPERT are used to determine global significance, pG. (A) SPIA two-way evidence plot. Each dot represents a pathway that contains at least one DEG. The impact analysis plots each pathway based on pNDE and pPERT. Pathways above the solid blue line are significant following FDR correction (pGFDR \< 0.05). Pathways above the solid red line are significant following Bonferroni correction (pGFWER \< 0.05). (B) A table of all significant pathways (PGFDR \<0.05) and their respective status is shown.](pone.0234993.g007){#pone.0234993.g007}

10.1371/journal.pone.0234993.t001

###### Select inflammatory and immune response genes.

![](pone.0234993.t001){#pone.0234993.t001g}

                               Gene Symbol   Log~2~ Fold Change   p-value (adjusted)                                                               Function (Uniprot ID)
  ---------------------------- ------------- -------------------- -------------------------------------------------------------------------------- --------------------------------------------------------------------------
  Interferon Related           OASL          1.923812             7.63E-18                                                                         Type I/II interferon signaling pathway--RNA binding (Q15646)
  IFITM1                       1.336366      1.99E-13             Type I/II interferon signaling pathway--Inhibits entry of virus (P13164)         
  IFIT3                        1.228324      6.81E-11             Type I/II interferon signaling pathway--Inhibits viral processes (O14879)        
  IFIT1                        1.4001        1.51E-10             Type I interferon signaling pathway--RNA binding (P09914)                        
  RSAD2                        1.424712      7.87E-09             Type I interferon signaling pathway--CD4+ T-cell activation (Q8WXG1)             
  OAS2                         1.064886      3.93E-06             Type I/II interferon signaling pathway--Innate antiviral response (P29728)       
  OAS1                         1.061772      1.35E-05             Type I/II interferon signaling pathway--Innate antiviral response (P00973)       
  IFITM3                       0.677765      2.45E-05             Type I/II interferon signaling pathway--Inhibits entry of virus (Q01628)         
  IFI27                        0.865445      0.000102             Type I interferon signaling pathway--Innate immune response (P40305)             
  IFITM2                       0.57169       0.000815             Type I/II interferon signaling pathway--Inhibits entry of virus (Q01629)         
  IRF7                         0.764681      0.004436             Type I/II interferon signaling pathway--Key transcriptional regulator (Q92985)   
  OAS3                         0.72591       0.008201             Type I/II interferon signaling pathway--Innate antiviral response (Q9Y6K5)       
  IFI35                        0.759788      0.012529             Type I interferon signaling pathway (P80217)                                     
  GBP2                         0.400131      0.049661             Type I/II interferon signaling pathway--anti-pathogen activity (P32456)          
  STAT1                        0.734634      1.89E-05             Signal transducer--Mediates interferon response (P42224)                         
  STAT2                        0.45657       0.026725             Signal transducer--Mediates interferon response (P52630)                         
  Chemokine/cytokine Related   CCL5          1.355304             4.67E-09                                                                         Chemotaxis--Monocytes, T-helper cells, eosinophils, neutrophils (P13501)
  CXCL2                        0.927644      3.00E-07             Chemotaxis--Leukocytes, neutrophils (P19875)                                     
  CXCL1                        0.734937      1.35E-05             Chemotaxis--Neutrophils (P09341)                                                 
  CXCL6                        0.654966      2.30E-05             Chemotaxis--Neutrophils, leukocytes (P80162)                                     
  CCL2                         0.479371      0.002206             Chemotaxis--Monocytes, basophils (P13500)                                        
  CXCL3                        0.837774      0.005424             Chemotaxis--Leukocytes, neutrophils (P19876)                                     
  ELANE                        0.819051      0.007334             Modulates natural killer cells, monocytes, granulocytes, neutrophils (P08246)    
  CXCL5                        0.652521      0.009551             Chemotaxis--Neutrophils, leukocytes (P42830)                                     
  CCR7                         0.659729      0.009835             Chemokine receptor--mediates immune cell chemotaxis (P32248)                     
  CCL13                        0.714727      0.032672             Chemotaxis--Monocytes, lymphocytes, basophils, eosinophils (Q99616)              
  C3                           0.68928       0.037701             Complement system (P01024)                                                       

B. burgdorferi infection induces a chemokine profile in HCPECs conducive to the chemotaxis of immune cells {#sec013}
----------------------------------------------------------------------------------------------------------

Many of the transcripts that were upregulated were categorized into pro-inflammatory cytokines and chemokines ([Table 1](#pone.0234993.t001){ref-type="table"})---these involved the C-X-C and C-C motif family of chemokines. *cxcl1*, *cxcl2*, *cxcl3*, *cxcl5*, and *cxcl6* showed elevated levels in response to *B*. *burgdorferi* infection. In addition to their role in modulating immune cell activation and inflammation, these chemokines provide a mechanism for the chemotaxis of immune cells. Predominantly, the C-X-C family possesses chemoattractant properties for leukocytes, such as neutrophils \[[@pone.0234993.ref061]--[@pone.0234993.ref063]\]. In fact, Cxcl1 mediates the recruitment of neutrophils and subsequent swelling in Lyme arthritis and carditis \[[@pone.0234993.ref064]\]. In contrast, the C-C family induces the migration of PBMCs, including lymphocytes and monocytes \[[@pone.0234993.ref065]\]. In our experiments, *ccl2*, *ccl5*, *ccl13*, and the receptor, *ccr7*, were found to be upregulated. This is corroborated in a study that previously showed *ccl2* (*mcp-1*) and *ccl5* (*rantes*) were elevated in human monocytes in response to *B*. *burgdorferi* \[[@pone.0234993.ref066]\]. Ccr7, a receptor for Ccl19 and Ccl21, is constitutively expressed in intestinal and gastric epithelial cells and has been shown to be upregulated in response to *Helicobacter pylori* infection \[[@pone.0234993.ref067], [@pone.0234993.ref068]\]. Biological process analysis performed by GO, via STRING, indicates cytokine and chemokine-mediated signaling pathways to be significantly enriched. Moreover, processes involving the regulation of leukocyte and neutrophil chemotaxis were shown to be enriched as well ([Fig 5B](#pone.0234993.g005){ref-type="fig"}). These observations are further strengthened by SPIA, where the pathways cytokine-cytokine receptor interaction and chemokine signaling pathways were found to be significantly enriched and activated ([Fig 7](#pone.0234993.g007){ref-type="fig"}). Further evidence that may imply the immune trafficking role of HCPECs comes from the secretion of these proteins at elevated levels within the culture media, as previously stated ([Fig 3B--3E](#pone.0234993.g003){ref-type="fig"}).

B. burgdorferi effects on cellular components involved in cell-cell junctions and adhesion {#sec014}
------------------------------------------------------------------------------------------

Although HCPECs were grown in a non-barrier monolayer culture, it was found that a number of genes related to cellular junctions and adhesion were modestly downregulated ([Table 2](#pone.0234993.t002){ref-type="table"}). The integrity of the BCSFB at choroid plexus epithelium is contingent on the presence of several tight and adherens junctions. Adherens junctions, found more basal than tight junctions ([Fig 1](#pone.0234993.g001){ref-type="fig"}), mainly involve cadherin proteins, for example E-cadherin, VE-cadherin, and N-cadherin \[[@pone.0234993.ref069]\]. The presence of CDH2(N-cadherin) has been observed on the basolateral side of the choroid plexus epithelium in mice \[[@pone.0234993.ref070]\]. Three genes within the cadherin superfamily were found to be downregulated--*cdh2*, *pcdh7*, and *pcdh10*. Likewise, genes that code for tight junction components showed lowered expression--*cldn14* and *magi1*. Genes within regulatory pathways that promote the formation of these junctions or other cellular adhesins were also found to have decreased expression--*mtss1*, *atp1b1*, and *frmd4a*. Network analysis showed minimal clustering of genes involved in cellular adhesion regarding protein-protein interactions ([Fig 6A](#pone.0234993.g006){ref-type="fig"}). Additionally, genes involved in the modulation of surrounding extracellular matrix and vasculature were observed to be downregulated, some of which shared overlapping function with cellular adhesion--*mmp1*, *flt1*, *vegfc*, and *serpine1*. GO enrichment indicated enriched cellular components that involve cell-cell junction and bicellular tight junctions, as well as angiogenesis and epithelium development processes. Pathway analysis indicates an inhibition of the focal adhesion pathway ([Fig 7](#pone.0234993.g007){ref-type="fig"}). The functional and structural impact of these downregulated genes in response to *B*. *burgdorferi* infection is yet to be determined in an animal model.

10.1371/journal.pone.0234993.t002

###### Select genes involved in cell-cell junctions, tight junctions, and adherens junctions.

![](pone.0234993.t002){#pone.0234993.t002g}

                         Gene Symbol   Log~2~ Fold Change   p-value (adjusted)                                                                      Function (Uniprot ID)
  ---------------------- ------------- -------------------- --------------------------------------------------------------------------------------- --------------------------------------------------------
  Functional component   CLDN14        -0.77849             0.014354                                                                                Tight junction protein; Cell adhesion (O95500)
  PCDH10                 -0.70536      0.000243             Protocadherin; cell-cell adhesion (Q9P2E7)                                              
  CDH2                   -0.65003      3.70E-07             Adherens junction protein; Cell adhesion (P19022)                                       
  MAGI1                  -0.42719      0.03935              Scaffolding/Tight Junction Protein; Cell adhesion (Q96QZ7)                              
  PCDH7                  -0.39693      0.011885             Protocadherin; cell-cell adhesion (O60245)                                              
  Regulatory component   PODXL         -0.97617             6.91E-07                                                                                Positive/negative regulation of cell adhesion (O00592)
  TWF1                   -0.67896      0.038453             Actin binding; Cadherin binding; Focal adhesion (Q12792)                                
  NEXN                   -0.63395      0.015809             Actin binding protein; Cell adhesion (Q0ZGT2)                                           
  MTSS1                  -0.53155      0.000231             Actin binding protein; Positive regulation of cell-cell junctions, adhesion (O43312)    
  FLT1                   -0.50364      0.01255              VEGF receptor; Endothelial proliferation, survival, cell adhesion (P17948)              
  ATP1B1                 -0.47766      0.034878             ATPase non-catalytic beta subunit; Cell adhesion; Epithelial cell polarity (PO5026)     
  MYLK                   -0.43527      0.014211             Regulates tight junctions; Regulates epithelial cell survival, wound healing (Q15746)   
  CCND1                  -0.37679      0.008102             Regulates cell cycle; Interactions with tight junction proteins (P24385)                
  FRMD4A                 -0.3571       0.017093             Scaffolding Protein--Regulates epithelial cell polarity, adherens junctions (Q9P2Q2)    
  CAPN2                  -0.33762      0.047708             Protease; Negative regulation of junction and adhesive pathways (P17655)                
  PALLD                  -0.30542      0.041217             Scaffolding/Cytoskeletal protein; Cell adhesion (Q8WX93)                                

Discussion {#sec015}
==========

The neurological symptoms associated with Lyme disease are largely attributed to the dissemination of *Borrelia burgdorferi* into the CNS and the resulting host immune response. While previous studies have investigated the effects of this bacteria on endothelial models of the BBB, little is known about its impact on the epithelium of the choroid plexus which comprises the BCSFB. The CP epithelium is situated at a key interface that separates the blood from the CSF and has repeatedly been shown to play an important role in modulating the immune response between the periphery and CNS during infection. The importance of the composition of the CSF in regards to cytokines and infiltrating immune cells in Lyme disease patients has been previously reported \[[@pone.0234993.ref012], [@pone.0234993.ref023], [@pone.0234993.ref071]--[@pone.0234993.ref073]\]. However, in the context of Lyme disease, the choroid plexus has been greatly understudied, and given its role as the major producer of CSF, as well as its ability to regulate its composition, it constitutes a major gap in knowledge for the pathophysiology of the disease \[[@pone.0234993.ref074]\]. To the best of our knowledge, this is the first study to directly investigate the impact of *Borrelia burgdorferi sensu lato* on choroid plexus epithelium.

This study demonstrates a robust change in gene expression in HCPECs induced by *B*. *burgdorferi* infection. The most prevalent outcome was the upregulation in immune and inflammatory response genes that were primarily categorized within the chemokine/cytokine mediated pathways and type I and II interferon pathways. Consistent with our report, previous studies have observed similar results regarding the inflammatory and immune response within monocytes, macrophages, and dendritic cells, showing an increase in cytokines such as *cxcl1*, *cxcl2*, *ccl2*, and *ccl5* \[[@pone.0234993.ref075], [@pone.0234993.ref076]\]. Likewise, interferon-stimulated genes within a murine model were reported to be upregulated, involving the transcripts *Ifit1*, *Ifit3*, and *Irf7* \[[@pone.0234993.ref055]\]. Irf7 has been shown to be a master regulator of interferon stimulated genes, and in conjunction with the upregulation of *ddx58* (*rig-I*), *ifih1* (*mda4*), and *trim25*, may provide insight into the activation of the interferon pathway being observed. Additionally, the induction of inflammatory cytokines including type I and type III interferons were reported when human PBMCs were infected with *B*. *burgdorferi* \[[@pone.0234993.ref077]\]. Furthermore, when characterizing the immunophenotypes of infiltrating immune cells and cytokines within the erythema migrans (EM) lesions of patients, T cells, monocytes, macrophages, and dendritic cells were found to be enriched in addition to inflammatory cytokines \[[@pone.0234993.ref078]\].

While this study shows overlapping features common in other cell types or animal models infected with *Bb*, the importance of the choroid plexus's role in immune cell trafficking is further highlighted in other models of infection and disease. The concept of the immunosurvellience activity within the choroid plexus is not new, and the abundance of immune cells found within the choroid plexus and subsequent transmigration following infection or insult has been widely reported \[[@pone.0234993.ref027], [@pone.0234993.ref030], [@pone.0234993.ref032], [@pone.0234993.ref079], [@pone.0234993.ref080]\]. Functional and pathway analysis indicates that many of these genes are involved in chemotaxis of immune cells \[[@pone.0234993.ref061], [@pone.0234993.ref062], [@pone.0234993.ref081]--[@pone.0234993.ref084]\]. In fact, *Cxcl1* (previously known as *Kc*) and *Ccl2* (previously known as *Mcp-1*) have been shown to mediate the recruitment of neutrophils into the joints of mice infected with *B*. *burgdorferi*, and are required for the development of Lyme arthritis \[[@pone.0234993.ref085]\]. The upregulation of *cxcl1*, *cxcl2*, *cxcl3*, *ccl2*, and *ccl5*, potent chemoattractants for immune cells including neutrophils, monocytes, and T cells, among others, have also been consistently reported to be elevated in other bacterial infections of the CP. In a barrier model of the choroid plexus involving infection with *Neisseria meningitidis*, in addition to an increase in these chemoattractants, the recruitment and subsequent transmigration of polymorphonuclear neutrophils and monocytes was observed \[[@pone.0234993.ref086], [@pone.0234993.ref087]\]. Similar results are also seen in response to *Streptococcus suis*, a gram-positive bacterium that can be transmitted to humans from pigs, leading to symptoms such as meningitis \[[@pone.0234993.ref088]\]. In a BCSFB model using human choroid plexus papilloma cells, a viral infection with Echovirus 30 showed an enhanced secretion of Cxcl1, Cxcl2, Cxcl3, and Ccl5 \[[@pone.0234993.ref089]\]. Indeed, when investigating the composition of the CSF from individuals with *B*. *burgdorferi* induced meningoradiculitis, an increase in inflammatory cytokines and a large number of B cells and plasma cells are observed \[[@pone.0234993.ref090]\]. Collectively, the choroid plexus has been shown to contribute significantly to the pathogenesis of many diseases and in regards to Lyme disease, our data implies that the choroid plexus may play an important role in the abundance of immune cell invasion of the CSF and the exacerbation of CNS inflammation that is seen in patients \[[@pone.0234993.ref091], [@pone.0234993.ref092]\].

In our current model, our transcriptome analysis indicates a downregulation of key tight junction and adherens junction genes, as well as regulatory cell adhesion genes. *cldn14*, a tight junction protein associated with the choroid plexus, as well as *cdh2*, an adherens junction protein, were found to be downregulated \[[@pone.0234993.ref093], [@pone.0234993.ref094]\]. The injection of LPS in mice to stimulate a peripheral inflammatory response showed a similar gene expression pattern, where the majority of upregulated genes within the choroid plexus involved immune-mediated pathways, while downregulated genes participated in barrier function, including claudins and protocadherins \[[@pone.0234993.ref095]\]. Though the functions of protocadherins are still being fully elucidated, they have been found to play a key role in cellular adhesion and barrier integrity \[[@pone.0234993.ref096], [@pone.0234993.ref097]\]. In addition, the sodium/potassium transporter beta subunit, *atp1b1*, was found to be downregulated, yet, seems to be an unlikely participant in the formation of cell-cell junctions; however, it has been shown to play an integral part in cell adhesion and in both the formation and maintenance of tight junctions in epithelial cells \[[@pone.0234993.ref098]--[@pone.0234993.ref101]\]. The downregulation of a number of these components, as well as scaffolding and other regulatory genes such as *magi1* and *mtss1*, would indicate a potential dysregulation of the choroid plexus barrier. This may lead to the possibility of immune cell invasion as well as an entry site for *Borrelia burgdorferi* into the CSF. In fact, the choroid plexus has already been implicated as a possible site of entry for both *N*. *meningitidis* and *S*. *suis*, specifically from the basolateral side \[[@pone.0234993.ref102]\]. By using two *in vitro* barrier models constructed by human brain microvascular endothelial cells (BMEC) and umbilical vein endothelial cells (HUVEC), *Bb* was found to differentially transverse these barrier systems \[[@pone.0234993.ref103]--[@pone.0234993.ref105]\]. While *B*. *burgdorferi*was capable of crossing the HUVEC monolayer, the traversal of the bacteria across the BMEC barrier required the addition of plasminogen and was found to induce the expression of plasminogen activators, receptors, and matrix metalloproteinases--supporting the concept that the bacteria is able to utilize the fibrinolytic system which may promote its dissemination through the degradation of the extracellular matrix and cell-to-cell junctions \[[@pone.0234993.ref103]--[@pone.0234993.ref105]\]. However, in our experiments, we found conflicting results--tissue plasminogen activator, tPA (*plat*), as well as its inhibitor, *serpine1*, were both found to be down regulated. Furthermore, the metalloproteinases, *mmp1*, and *adamts15*, were found to be downregulated and upregulated, respectively. Though our system does not represent a barrier model, the observed outcome lends credibility for our future studies involving *B*. *burgdorferi* infection in an *in vivo* model to explore the impact of systemic infection on the BCSFB.

Conclusion {#sec016}
==========

Following infection of HCPECs with *Borrelia burgdorferi*, we identified a gene expression pattern that is marked by a robust increase in immune and inflammatory genes within the cytokine/chemokine pathways and type I and II interferon pathways. Protein analysis showed an enhanced secretion of these inflammatory and chemotactic cytokines. Additionally, the downregulation of genes involved in cell-cell adhesion, adherens junctions, and tight junctions was observed. Overall, our data indicates that the choroid plexus, like in many other infectious diseases, may play a key role in the pathogenesis of Lyme neuroborreliosis through the induction of inflammatory factors, the promotion of immune cell migration, and potentially through the dysregulation of the BCSFB. Our future studies will aim to elucidate the impact of *B*. *burgdorferi* infection on the BCSFB integrity within an *in vivo* model. By understanding how the inflammatory and immune response is modulated within the CNS, as well as mechanisms by which *Borrelia burgdorferi* is able to traverse into the CNS, new treatments for Lyme disease can be developed.
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Please find our response to the reviewers below, indicated by bullet points.

Reviewer \#1: The manuscript by Thompson et al assesses inflammatory responses of human choroid plexus epithelial cells in response to stimulation with the Lyme disease spirochete Borrelia burgdorferi. The major weakness with this manuscript is that the authors did not establish a fold-change cutoff to their RNA-seq data. This makes the analysis highly susceptible to Type 1 error, particularly where only 3 biological replicates were used for each condition. The authors claimed that several hundred genes were differentially expressed, but the vast majority of these had a very modest fold-change in expression, casting doubt on the biological significance of these results. In addition, qRT-PCR and cytokine data show minor changes in expression/protein levels, and the manuscript suffers from over-stating these modest changes that may or may not be biologically relevant. In order to be appropriate for publication, a much more critical analysis of the data will be required. The manuscript would also be greatly enhanced by increasing the number of samples for each group. Figure 3 shows marked variability between samples, which suggests much of the data are simply statistical noise.

• We appreciate the thorough and careful input provided by Reviewer \#1, especially regarding statistical and biological significance of our experiments.

• Regarding not establishing a fold-change cutoff: It is our understanding that establishing a fold-change cutoff is typically an arbitrary value and is usually used as a tool to reduce the number of differentially expressed genes to a manageable number (and selecting only the largest FC genes) for downstream analysis -- which we felt was not necessary for our gene list (258 DEG's). Therefore, selecting a fold-change cutoff would not remove any risk of a type 1 error, and would also introduce bias within our data. Additionally, a risk of a type 1 error is not directly tied to the magnitude of the fold change but more precisely to the raw read counts. In other words, it is more likely that a low transcript gene (i.e. 10 reads total) shows, by random chance, an increase of 10 reads within our treated group (10 -\> 20 = log2FC of 1) than a high transcript read (i.e. 10,000 reads) showing the same log2FC of 1 (i.e. 10,000 -\> 20,000). An example within in our data set would be PAMR1 -- this gene shows a low log2FC of 0.383 but a very high read count (control = 58469, treated = 77514.14. Statistically and biologically speaking, we feel that our results for low log2FC genes are not inherently at any greater risk of a type 1 error than other genes with a higher log2FC. However, we agree with the reviewer that type 1 errors are always a concern in these datasets, especially if a gene shows a low read count. In fact, our methods for data and statistical analysis took this into consideration and aimed to reduce these risks -- discussed below.

• The above example regarding low transcript reads and type 1 errors is typically a concern in all transcriptome related experiments. However, many statistical packages, such as DESeq2 which was used in our analysis (Citation \#42 in manuscript), corrects for these issues in a couple of different ways. Variability between replicates for each gene needs to be accurately modeled to test for differential expression. As quoted below from DESeq2 citation, studies with large sample sizes typically do not suffer from this short-coming, while smaller studies may show higher variability for each gene.

o "Accurate estimation of the dispersion parameter α i is critical for the statistical inference of differential expression. For studies with large sample sizes this is usually not a problem. For controlled experiments, however, sample sizes tend to be smaller (experimental designs with as little as two or three replicates are common and reasonable), resulting in highly variable dispersion estimates for each gene. If used directly, these noisy estimates would compromise the accuracy of differential expression testing."1 -- emphasis mine.

o To correct for these shortcomings in studies such as ours, for any specific gene, the expected variability for that gene is modeled based on other genes within the entire genome that share a similar average expression strength. The underlying assumption provided by the authors of DESeq2 state that genes of similar average expression strength will have similar dispersion. If we go back to the previous example of the low transcript gene with a read count of 10, DESeq2 will find all genes with a similar read count, determine the overall variability of these genes, and apply that model to this low transcript gene. If all low transcript genes showed only a variability of 10 +/- 1, statistically, our gene with a low transcript read changing from 10 -\> 20 would inherently have a lower risk of a type 1 error and the observed change may in fact be real. Based on this modeling, our gene would be corrected to have a "true" value change of 19 instead of the observed 20 -- this is called "shrinkage estimation of dispersion" by the authors of DESeq2. The authors use an empirical Bayes approach which bases this shrinkage on two factors 1) the above-mentioned method of "true" dispersion, and 2) the degrees of freedom of the experiment -- as we increase sample size, this shrinkage is reduced. Through this modeling, we can therefore correct and reduce the risk of a type 1 error for differentially expressed genes that show low transcripts as well as taking into account our sample size.

o Furthermore, DESeq2 applies a post hoc statistical test, Benjamini-Hochberg adjustment, to reduce the likelihood of a type 1 error. All significant differentially expressed genes within the RNA-seq data use this adjusted p-value (padj) to determine significance -- also called false discovery rate (FDR). A padj/FDR \< 0.05 was considered as significant.

o Based on the above explanation, we believe our statistical analysis of our RNA-seq data is quite conservative in its approach and is in-line with current standards.

• The reviewer next brings into question the biological significance of the results. Again, we want to thank the reviewer for their attention to detail in tying together statistical and biological significance. We agree with the reviewer that a low log2FC, even if statistically significant, may not have any biological relevance. However, we feel that biological relevance should not be limited to just the fold change and therefore sought to determine functional and pathway analysis to determine biological significance. A single low expressed cytokine would not prompt an immune response typically seen in Lyme disease patients, but based on our downstream analysis (STRING clustering, Gene ontology for functional analysis, and pathway analysis via SPIA), we observed that a large percentage of upregulated genes fall into inflammatory and immune response groups (Fig 5). By showing that a large number of interconnected inflammatory/immune related genes are upregulated, we feel these pathways demonstrate biological significance. Additionally, as cited in the discussion section, this study shows similar results to other studies of Lyme disease in different animal/cell models. Similar results are also seen within other models of infection of the choroid plexus.

o Regarding qRT-PCR and ELISA data: Both experiments were performed as a validation test of our RNA-seq data, as well as to determine if the observed transcriptome data translated to the protein level. The modest changes seen within both experiments mirror the changes seen in our RNA-seq and we view this as successful validation.

o Because of these reasons, we believe biological relevance has been established. However, we agree with the reviewer that, regarding the downregulated genes, biological relevance may not be as robust. We were quite excited to observe changes in cell-cell adhesion genes and, as discussed in the manuscript, aim to bring these experiments into an animal model to further establish biological relevance in structural changes of the choroid plexus. Due to the limitations of this project, we had aimed to down-play the biological significance of these downregulated changes (without completely ignoring them) by placing the inflammatory and immune response observations as the core of the manuscript.

• To overcome many of the stated shortcomings of the manuscript, the reviewer suggests increasing the number of samples. As briefly mentioned, as part of the modeling system of DESeq2, increasing the number of samples would in fact reduce variability of our system. While this would increase statistical power, it would not change the observed magnitude in log2FC. In fact, if we were to increase replicates, we would see a greater increase in the number of low log2FC genes as statistical power increased.

o If additional replicates were to be added at this point, our data would suffer from batch effect and increase variability. Even during sequencing, flow cell variability as well as inter-lane variability would also impact the results. Our methods for this manuscript took this into consideration -- all samples were pooled prior to shipment and therefore all samples were sequenced across two lanes in order to reduce variability.

o Regarding the reviewer's comment of Fig. 3: I am assuming the reviewer is addressing Fig 3B. The intended purpose of Fig 3B was to illustrate variability across replicates as well as across treatment groups. So, while there is some variability across replicates, there is much greater variability across treatment groups. This is evident based on the coloring scheme used, as well as the correlation clustering indicated at the top of the heatmap -- showing that control replicates cluster together and Infected groups cluster together.

Several minor concerns are noted below:

1\. Please use the correct the mouse nomenclature for genes, transcripts, and proteins as appropriate

• Corrected nomenclature for mice were added in the following sections:

o Page 21, line 398

o Page 22, line 434

o Page 23, lines 449-450

2\. Brain anatomy needs to be labeled in Fig 1 (particularly the choroid plexus)

• Figure 1 has been updated to reflect brain anatomy labels -- Choroid Plexus and Ventricles

3\. Methods needs a statistical analysis section clearly describing the types of statistical analyses performed for each experiment

• We appreciated the reviewer's comment for the need of a statistical analysis section. Statistical analysis for each experiment was stated in its relevant section, however, as stated, it would add clarity to the methods to reorganize this into its own section. A statistical analysis section has been added and can be found as the last section of the Methods. The statistical analysis section explains the methods used for RNA-seq, qRT-PCR, and ELISA.

4\. qRT-PCR data lack any post-hoc analysis

• We have taken the reviewer's advice and performed post-hoc analysis for multiple t-test comparisons. Specifically, we applied the Benjamini-Krieger-Yekutieli correction for determining the False Discovery Rate (FDR, p-adjusted)2. This is an improved procedure of their previous and standardized method, the Bejamini-Hochberg. Additionally, this updated procedure was the recommended correction provided by our statistical software (Graphpad PRISM) for multiple t-test comparisons. The outcome of this correction provided us with more conservative adjusted p-values and is reflected in the updated Figure 4. Significance was set to FDR \< 0.05.

5\. There are numerous abbreviations, many of which are used without spelling them out the first time they are introduced

• We were not able to identify instances within the manuscript that used an abbreviation without spelling it out the first time it was introduced. However, there were two instances in which words were abbreviated and spelled out for the first time in the abstract as opposed to the main body of the paper. We reintroduced two abbreviates within the manuscript body:

o Page 5, line 62 -- "cerebral spinal fluid (CSF)"

o Page 4, line 49 -- "central nervous system (CNS)"

6\. The manuscript would be easier to read if some of the abbreviations were eliminated.

• We appreciate the reviewer's attention to readability and have tried to minimize unnecessary abbreviations.

• Many abbreviations have been removed or changed, mainly involving "Bb" and "CP", to read easier.

o Some instances of Bb were changed to either "B. burgdorferi" or "Borrelia burgdorferi"

o Some instances of CP were changed to "choroid plexus".

Reviewer \#2: The report entitled \"the Lyme disease bacterium, Borrelia burgdorferi, stimulates an inflammatory response in human choroid plexus epithelial cells\" describes a transcriptomic analysis of this key nervous system cell type in response to stimulation with Bb. Overall, the paper is well-organized and written. The hypothesis is clearly stated and in general, the conclusions are supported by the data. A few minor concerns/changes are noted.

-Perhaps it was missed, but the raw data should be uploaded into a public data base.

• The raw data will be uploaded to the GEO repository upon notice of acceptance. The accession number will be provided at that time.

-p10, line 174-175 \"samples were pooled..\" How many?

• For RNA sequencing, there were 6 samples total -- 3 Control (non-infected), and 3 Infected with Bb. The number of samples were briefly stated on Page 13, Line 249 of the original document; however, after review, the number of samples could be more clearly defined. To clarify the number of samples used, the following was added within the Methods section:

o Page 8, Line 141-143: "Two groups were used for these experiments -- Control, non-infected (N=3) and Infected, 48 hours (N=3); a total of 6 samples."

o Page 10, Line 180-181, underlined the edited portion: "All samples, 3 control and 3 infected, were then pooled and sent to Novogene...."

-line 167 samples were \"run\"

• Corrected. "ran" to "run"

-p11 line 209 spell out actb

• As the sentence referred directly to the gene "...normalized to the housekeeping gene actb", "actb" was kept but "β-actin" was added directly after in parentheses to clarify -- "...normalized to the housekeeping gene actb (β-actin)"

-in Fig. 4, what is \"n\"? What do the black versus grey bars represent?

• The "n" for figure 4A is found in the figure legend -- "n=3", Page 15, Line 291. For Figure 4B-E, "n=3" was added, Page 16, Line 312.

• The black and grey bars do not represent anything and were simply added to visually enhance the figure. All bars are labeled accordingly at the bottom of each graph.

-p19 line 372 genes with cellular junctions were \"modestly\" downregulated.

• "Modestly" was added to more accurately communicate the magnitude of change that was observed.

-p23 line 438 reference needed. What are CP papilloma cells?

• Reference added, \#88; all subsequent reference \#'s updated

-(throughout\": our data \"suggest\"

• We assumed the reviewer meant that the word "suggest" was used to often. We changed this word in a few instances to synonyms to make the manuscript more readable -- "imply", "indicate", etc.

-p24, line 464 reference needed

• Originally, references 103-105 refer to two sentences and was placed at the end of the second sentence. These references have been added to the end of both sentences.
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